C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter C—Drugs: GeneralPart 210—Current Good Manufacturing Practice in Manufacturing, Processing, Packing, Or Holding of Drugs; General

21 C.F.R. § 210.1 (2026)

Status of current good manufacturing practice regulations

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 ACTIVE · 8 IN 5Y cited 1981–2026 23citing cases
At a glance

Courts have cited this section in 23 opinions since 1981, 8 of them in the last five years. The most litigated part is subsection (a) (2 cases).

(a) The regulations set forth in this part and in parts 211, 213, 225, and 226 of this chapter contain the minimum current good manufacturing practice for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or holding of a drug to assure that such drug meets the requirements of the act as to safety, and has the identity and strength and meets the quality and purity characteristics that it purports or is represented to possess.

(b) The failure to comply with any regulation set forth in this part and in parts 211, 213, 225, and 226 of this chapter in the manufacture, processing, packing, or holding of a drug shall render such drug to be adulterated under section 501(a)(2)(B) of the act and such drug, as well as the person who is responsible for the failure to comply, shall be subject to regulatory action.

(c) Owners and operators of establishments engaged in the recovery, donor screening, testing (including donor testing), processing, storage, labeling, packaging, or distribution of human cells, tissues, and cellular and tissue-based products (HCT/Ps), as defined in § 1271.3(d) of this chapter, that are drugs (subject to review under an application submitted under section 505 of the act or under a biological product license application under section 351 of the Public Health Service Act), are subject to the donor-eligibility and applicable current good tissue practice procedures set forth in part 1271 subparts C and D of this chapter, in addition to the regulations in this part and in parts 211, 225, and 226 of this chapter. Failure to comply with any applicable regulation set forth in this part, in parts 211, 225, and 226 of this chapter, in part 1271 subpart C of this chapter, or in part 1271 subpart D of this chapter with respect to the manufacture, processing, packing or holding of a drug, renders an HCT/P adulterated under section 501(a)(2)(B) of the act. Such HCT/P, as well as the person who is responsible for the failure to comply, is subject to regulatory action.

[43 FR 45076, Sept. 29, 1978, as amended at 69 FR 29828, May 25, 2004; 74 FR 65431, Dec. 10, 2009; 89 FR 51769, June 18, 2024]
The 20 cases that cite 21 C.F.R. § 210.1 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENUS ex rel. Barry Rostholder v. Omnicare, Inc., 745 F.3d 694 (4th Cir. 2014).
cites § 210.1 1×cited by 55 cases
Where it cites § 210.1
“§§ 331 , 351(a)(2)(B); see also 21 C.F.R. 210.1 (failure to comply with the CGMPs renders a drug “adulterated”).”
The case’s holding
A False Claims Act claim requires a relator to plausibly allege a false statement or fraudulent course of conduct, requisite scienter, materiality, and causation of government payment.
Later courts cite it for
“to plead an fca claim, a relator must plausibly allege four distinct elements: (1) there was a false statement or fraudulent course of conduct; (2) made or carried out with the requisite scienter knowledge; (3) that was material; and (4) that caused the government to pay out money or to forfeit moneys due (i.e., that involved a 'claim')(emphasis added).” · 6 citing courts
2
GREENUnited States v. Richlyn Labs., Inc., 827 F. Supp. 1145 (E.D. Pa. 1992).
cites § 210.1 3×subsections: (a)cited by 12 cases
Where it cites § 210.1
“: 21 C.F.R. §§ 210.1 , 211.1. Regular and continuing training of all employees and personnel in current good manufacturing practices by qualified individuals is also expected.”
Later courts cite it for
“indeed, because congress has seen fit to act in a given area by enacting a statute, irreparable injury must be presumed in a statutory enforcement action.” · 2 citing courts
3
GREENRiggs v. Home Builders Inst., 203 F. Supp. 2d 1 (D.D.C. 2002).
cites § 210.1 1×cited by 37 cases
Where it cites § 210.1
“at 1331 (citing 21 C.F.R. §§ 210.1 (b), 211,142(b); 21 U.”
The case’s holding
An at-will employee may state a wrongful discharge claim under the public-policy exception if fired for refusing to violate a statute or regulation reflecting clear public policy.
4
GREENUnited States v. Barr Labs., Inc., 812 F. Supp. 458 (D.N.J. 1993).
cites § 210.1 2×cited by 13 cases
Where it cites § 210.1
“21 C.F.R. § 210.1 (b). 9. Congress recognizes the United States Pharmacopeia (“USP”), a nonprofit corporation which develops drug product standards with the help of professionals from academia, the medical community, the pharmaceutical industry and the FDA, as an official…”
5
GREENLiberatore, James v. Melville Corp, 168 F.3d 1326 (D.C. Cir. 1999).
cites § 210.1 1×cited by 42 cases
Where it cites § 210.1
“§ 351 , see 21 C.F.R. § 210.1 (b), and the violator is subject to a fine, imprisonment up to one year, or both.”
The case’s holding
An at-will employee states a claim for wrongful discharge when terminated for threatening to report an employer's violation of federal drug safety regulations.
Later courts cite it for
“an employee who serves at the will of his or her employer may be discharged 'at any time and for any reason, or for no reason at all.” · 10 citing courts
6
GREENUnited States v. Merck & Co., 44 F. Supp. 3d 581 (E.D. Pa. 2014).
cites § 210.1 1×cited by 9 cases
Where it cites § 210.1
“12 (b); 21 C.F.R. § 210.1 et seq., and duties to the National Vaccine Program and the Vaccine Injury Compensation Program.”
7
GREENUnited States v. Richlyn Labs., Inc., 822 F. Supp. 268 (E.D. Pa. 1993).
cites § 210.1 2×cited by 6 cases
Where it cites § 210.1
“: 21 C.F.R. §§ 210.1 , 211.1. Regular and continuing training of all employees and personnel in current good manufacturing practices by qualified individuals is also expected.”
8
cites § 210.1 1×cited by 13 cases
Where it cites § 210.1
“21 C.F.R. § 210.1 (b) (1983). 5 . 525 F.2d 130, 133-34 (2d Cir.”
Later courts cite it for
“sufficiently definite and precise to comport with constitutional standards and are not arbitrary or capricious on grounds of vagueness.” · 2 citing courts
9
GREENOregon ex rel. Kroger v. Johnson & Johnson, 832 F. Supp. 2d 1250 (D. Or. 2011).
cites § 210.1 1×cited by 5 cases
Where it cites § 210.1
“” 21 C.F.R. § 210.1 (a). Failure to comply with cGMPs renders a drug “adulterated.”
10
GREENUnited States v. Premo Pharm. Labs., Inc., 511 F. Supp. 958 (D.N.J. 1981).
cites § 210.1 1×cited by 9 cases
Where it cites § 210.1
“FDA’s Good Manufacturing Practice (GMP) regulations, 21 C.F.R. § 210.1 et seq. (1980), are not sufficient to avoid the need for preclearance.”
11
GREENWright v. Fred Hutchinson Cancer Rsch. Ctr., 269 F. Supp. 2d 1286 (W.D. Wash. 2002).
cites § 210.1 1×cited by 2 cases
Later courts cite it for
“failed to disclose certain important facts regarding the protocol and their own pecuniary interests in the outcome of the experiments.” · 1 citing court
cites § 210.1 1×cited by 1 case
Where it cites § 210.1
“See 21 C.F.R. § 210.1 (a) (2011) ("The regulations set forth in this part and in parts 211, 225, and 226 of this chapter contain the minimum current good manufacturing practice for methods to be used in, and the facilities or controls to be used for, the manufacture, processing,…”
13
NEUTRALMylan Pharm. Inc. v. United Steel, 471 F. Supp. 2d 667 (N.D. W. Va. 2007).
cites § 210.1 2×cited by 1 case
Where it cites § 210.1
“21 C.F.R. § 210.1 (a). Moreover, the failure of a person to comply with those GMPs in the manufacturing, processing, packing, or holding of a drug shall render that drug “adulterated” and subject the person to regulatory action.”
14
NO FLAGShareholder Rep. Servs., LLC v. Alexion Pharm., Inc., No. 2020-1069-MTZ (Del. Ch. May 27, 2026).
cites § 210.1 4×cited by 0 cases
Where it cites § 210.1
“29, 1978); 21 C.F.R. § 210.1 (a) (“The regulations set forth in this part and in parts 211, 213, 225, and 226 of this chapter contain the minimum current good manufacturing practice for .”
15
NO FLAGTorrent Pharma, Inc. v. Priority Healthcare Distrib., Inc., No. N18C-05-094 CEB, 2022 WL 3272421 (Del. Super. Ct. Aug. 11, 2022).
cites § 210.1 3×cited by 0 cases
Where it cites § 210.1
“For example, the Operating Guidelines designate CuraScript as the party “responsible” for all “physical inventory,” including “packing” and “putting away” Torrent’s products.22 19 Patricia I. Carter, Federal Regulations of Pharmaceuticals in the United States and Canada, 21 Loy.”
16
GREENAvKARE, Inc. v. United States, 125 Fed. Cl. 11 (Fed. Cl. 2016).
cites § 210.1 1×cited by 0 cases
Where it cites § 210.1
“” 21 C.F.R. § 210.1 (a). Clause AS8005 specifically requests information about the "location and owner of [the] facility where [the] ingredients are measured, weighed, mixed and compounded;” the "location of facilities where intermediate containers will be fixed and labeled;”…”
17
NO FLAGUnited States ex rel. Yu v. Grifols USA, LLC, No. 22-107-cv, 2022 WL 7785044 (2d Cir. Oct. 14, 2022).
cites § 210.1 2×cited by 0 casesunpublished
Where it cites § 210.1
“” 21 C.F.R. § 210.1 . The FDCA prohibits the sale or manufacture of any drug that is “adulterated.”
18
NO FLAGIn re Target Corp. BPO Sales & Mktg. Litig., No. 0:24-cv-01323 (D. Minn. Jan. 20, 2026).
cites § 210.1 2×subsections: (a) 2×cited by 0 casesunknown
Where it cites § 210.1
“4, 2025); see 21 C.F.R. § 210.1(a). The cGMPs provide minimum current good manufacturing practice for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or holding of a drug to assure that such drug meets the requirements…”
19
NO FLAGUnited States ex rel. Allen Timothy Yu v. Grifols USA, LLC, No. 1:17-cv-02226, 2021 WL 5827047 (S.D.N.Y. Dec. 8, 2021).
cites § 210.1 1×cited by 0 casesunknown
Where it cites § 210.1
“21 C.F.R. § 210.1 . ii. Grifols and IVIG Products Plaintiff is the United States.”
20
NO FLAGStephen Krahling v. Merck & Co Inc, No. 23-2553 (3d Cir. Aug. 6, 2024).
cites § 210.1 1×cited by 0 casesunpublished
Where it cites § 210.1
“]” 21 C.F.R. § 210.1 (a). The contract does not expressly provide that cGMP compliance is a condition of payment, only that cGMP “will be the standard [] applied for manufacturing, processing and packing of drugs, chemicals, biologicals, and reagents[,]” FCA App.”

Show all 23 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
198120032026

One bar per year. Tallest: 2 cases in 1993. 2026 is a partial year. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
E.D. Pa.33rd Cir.2D.N.J.2S.D.N.Y.2N.D.W. Va.2Bankr. E.D. Ark.12d Cir.14th Cir.1

The 8 courts with the most citing cases, of 17 courts in all.

By subsection
(a)2 cases
United States v. Richlyn Labs., Inc., 827 F. Supp. 1145 (E.D. Pa. 1992).“: 21 C.F.R. §§ 210.1 , 211.1. Regular and continuing training of all employees and personnel in current good manufacturing practices by qualified individuals is also expected.”
In re Target Corp. BPO Sales & Mktg. Litig., No. 0:24-cv-01323 (D. Minn. Jan. 20, 2026).“4, 2025); see 21 C.F.R. § 210.1(a). The cGMPs provide minimum current good manufacturing practice for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or holding of a drug to assure that such drug meets the requirements…”

Show all 23 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com